相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma
Maqbool Ahmed et al.
CARCINOGENESIS (2014)
mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia
Luokun Xie et al.
JOURNAL OF IMMUNOLOGY (2014)
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype
Lucia Lisi et al.
JOURNAL OF NEUROINFLAMMATION (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Qingsong Liu et al.
CANCER RESEARCH (2013)
Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors
Zhi Rong Qian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice
Juyeon Park et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2012)
A unifying model for mTORC1-mediated regulation of mRNA translation
Carson C. Thoreen et al.
NATURE (2012)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Raparnycin (mTOR) Inhibitor for Treatment of Cancer
Qingsong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The tuberous sclerosis complex
Ksenia A. Orlova et al.
YEAR IN NEUROLOGY 2 (2010)
New Hierarchical Phosphorylation Pathway of the Translational Repressor eIF4E-binding Protein 1 (4E-BP1) in Ischemia-Reperfusion Stress
Maria I. Ayuso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
Michael W. Ronellenfitsch et al.
BRAIN (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Stability of phosphoprotein as a biological marker of tumor signaling
AF Baker et al.
CLINICAL CANCER RESEARCH (2005)
S6K1-/-/S6K2-/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway
M Pende et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer
JI Kreisberg et al.
CANCER RESEARCH (2004)
分享论文
